VACCINES
Vaccine and Infectious Disease Research Backed by Established Study Experience
Sequoia supports vaccine and infectious disease research through experienced investigators, established participant access, recruitment expertise, and coordinated study execution across a connected site network. Together, these capabilities help sponsors confidently advance vaccine research.
Vaccine Experience
Sequoia’s investigators bring extensive vaccine and infectious disease research experience across more than 200 trials and 28 indications. Their experience spans biodefense, pandemic, and routine vaccine programs, as well as a range of infectious disease targets, vaccine platforms, delivery approaches, and safety monitoring requirements.
- H5N1
- H3N2
- Hepatitis B
- Herpes Zoster
- Lyme Disease
- Meningococcal
- Nipah Virus
- Norovirus
- Pandemic Influenza
- Plague
- Pneumococcal
- Seasonal Influenza
- RSV
- Smallpox
- Traveler’s Diarrhea
- Tuberculosis
- West Nile Virus
- Yellow Fever
- Zika
- Anthrax
- Anti-orthopoxvirus
- Botulinum toxin
- Cholera
- COVID-19
- Chikungunya
- CMV
- Dengue
- Group B Streptococcus
Patient Access & Study Execution
Vaccine protocols require robust recruitment infrastructure to support participant identification, screening, scheduling, and follow-up. Sequoia combines centralized recruitment support with local participant engagement to build recruitment plans around protocol criteria and the patient populations available for each study.
200+
vaccine trials completed since 2005
25+
new drugs & vaccines brought to market
28
indications across biodefense, pandemic, and routine vaccines
65,000+
active patient charts
- Diverse patient population comprising 40% African American, 43% Caucasian, 8% Hispanic, 6% Asian, and 3% Native American.
- Capacity to enroll 150+ subjects per week
- Adult, elderly, and adolescent/pediatric populations covered, with 19% of participants aged 65+
- Several trials funded by DOD, BARDA, DMID and NIH
Supporting Investigators
Vaccine and infectious disease studies are supported by investigators with clinical research experience relevant to the protocol and target patient population.
Dr. Carlos Fierro is among the experienced investigators supporting Sequoia’s vaccine research. He has over 20 years of clinical research experience and has participated in 200+ studies for both small biotech companies and large pharmaceutical sponsors across private and government sectors.
Protocol-Specific Capabilities
Depending on protocol requirements, Sequoia can support specialized vaccine studies with PBMC laboratory services, onsite pharmacy, PK/PD support, cryogenic specimen storage, and IATA-certified specimen handling, along with both outpatient exam capacity and inpatient capabilities.
PBMC laboratory
Inpatient capabilities
Onsite pharmacy
PK/PD support
Cryogenic specimen storage
IATA-certified specimen handling
Outpatient exam capacity
NETWORK
Backed by the Sequoia Network
Every vaccine study benefits from shared operational support, standardized quality systems, and collaborative investigator expertise.
Five FDA inspections with zero Form 483 findings reflect Sequoia's commitment to consistent quality across every study.
Discuss Your Vaccine Study
Connect with Sequoia to explore investigator fit, patient access, and feasibility for your next vaccine clinical trial.
Frequently asked questions
What types of vaccine studies can Sequoia evaluate?
Sequoia evaluates vaccine and infectious disease protocols across a range of study designs and phases, matched to the operational and participant-access requirements of each protocol.
Which participant populations can Sequoia support?
Sequoia supports adult, elderly, adolescent, and pediatric populations, with a diverse participant base that includes 40% African American, 43% Caucasian, 8% Hispanic, 6% Asian, and 3% Native American. 19% of study participants are aged 65 and older.
How does Sequoia assess enrollment feasibility for vaccine protocols?
Sequoia assesses feasibility by evaluating protocol requirements against available participant populations, investigator experience, and operational capacity, including any seasonal or timeline-sensitive enrollment considerations.
What operational capabilities are available for complex vaccine studies?
Depending on protocol requirements, Sequoia can support specialized needs such as investigational product handling, specimen processing, and structured participant follow-up.
How are investigators and locations selected for a vaccine protocol?
Sequoia matches each vaccine protocol with investigators and sites across the network based on therapeutic fit, participant access, and operational requirements, rather than routing every study through a single location or investigator.